Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHAMOLIN vs AKRINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.
Not available; likely a combination product with antihistaminic and sympathomimetic actions.
FDA-approved: Treatment of esophageal varices that have recently bled to prevent rebleeding.,Off-label: Sclerotherapy of varicose veins, treatment of hemorrhoids, management of vascular malformations.
Allergic rhinitis,Nasal congestion
5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.
Adults: 100 mg orally twice daily.
Terminal elimination half-life is approximately 5-6 hours in adults with normal renal function; may be prolonged in renal impairment.
3-4 hours (prolonged to 8-12 hours in renal impairment; no dose adjustment typically needed unless Cr Cl <30 m L/min).
Ethanolamine oleate is metabolized in the liver via oxidation and conjugation; exact enzymes are not well characterized.
Not available; components may be metabolized via hepatic CYP enzymes.
Primarily renal excretion of unchanged drug and metabolites; >90% eliminated in urine within 24 hours, with less than 5% in feces.
Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal (5-10%).
Approximately 20-30% bound to plasma proteins, primarily albumin.
99.5% (primarily to albumin; also to α1-acid glycoprotein).
Volume of distribution is approximately 0.5-0.8 L/kg, indicating distribution into extracellular fluid.
0.10-0.17 L/kg (low, indicating limited extravascular distribution; primarily in central compartment).
Intravenous: 100%; intramuscular: approximately 90-95% due to first-pass metabolism.
Oral: 3-5% (extensive first-pass metabolism); IV: 100%.
No dose adjustment required for renal impairment.
GFR 30-59 m L/min: 50 mg daily; GFR <30 m L/min: 50 mg every other day.
Contraindicated in severe hepatic disease (Child-Pugh class C). Use with caution in Child-Pugh class A or B; no specific dose modification established.
Child-Pugh A: 100 mg twice daily; Child-Pugh B: 50 mg twice daily; Child-Pugh C: 50 mg daily.
Not recommended for use in children due to lack of safety and efficacy data.
Children (1-12 years): 2 mg/kg orally twice daily, max 100 mg/dose.
Use with caution; consider reduced dose due to increased risk of sclerotherapy complications. No specific dose adjustments established.
Adults >65 years: initiate at 50 mg twice daily, titrate to 100 mg twice daily as tolerated.
None explicitly required by FDA; however, severe adverse effects including anaphylaxis, renal failure, and esophageal ulceration have been reported.
None
Risk of anaphylaxis and hypersensitivity reactions; have emergency equipment available.,Risk of esophageal ulceration, stricture, or perforation when used for varices.,May cause hemolysis and hemoglobinuria; monitor renal function.,Use caution in patients with cardiopulmonary disease, as rapid injection may cause bradycardia or hypotension.
Use with caution in patients with hypertension,Avoid in patients with severe coronary artery disease
Known hypersensitivity to ethanolamine oleate or any component.,Active gastrointestinal bleeding (for elective sclerotherapy).,Severe hepatic impairment or portal hypertension with high risk of perforation.,Uncontrolled systemic infection.
Hypersensitivity to any component,Severe hypertension,Concomitant use with MAO inhibitors
No specific food interactions. Avoid oral intake immediately after procedure until gag reflex returns.
No known food interactions with topical naftifine. No dietary restrictions required.
Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and potential for fetal harm. No adequate, well-controlled studies in pregnant women.
FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, renal dysfunction, necrotizing enterocolitis, periventricular hemorrhage, and pulmonary hypertension.
It is not known whether ethanolamine oleate is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio: Not available.
Contraindicated during breastfeeding. M/P ratio not determined due to contraindication. Excreted into breast milk; potential for serious adverse effects in infant.
No specific dosing adjustments are recommended for pregnancy; however, use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect drug distribution, but no dose adjustment studies exist. Avoid use unless benefit clearly outweighs risk.
No established safe dose. Generally contraindicated during pregnancy. If used, lowest effective dose and shortest duration. Avoid after 20 weeks gestation.
Ethamolin (ethanolamine oleate) is a sclerosing agent used for esophageal varices. Administer via intravariceal injection; maximum dose per session is 20 m L. Monitor for anaphylaxis, chest pain, and esophageal ulceration. Do not use in patients with known hypersensitivity to ethanolamine or oleic acid.
AKRINOL is a topical antifungal (naftifine) that inhibits squalene epoxidase, effective against dermatophytes. Apply once daily for 2-4 weeks. Avoid occlusive dressings. Monitor for local irritation or allergic contact dermatitis.
This medication is injected into the veins in your esophagus to stop bleeding.,You may experience chest pain or difficulty swallowing after the procedure.,Avoid eating or drinking until the numbing medicine wears off to prevent choking.,Report any signs of allergic reaction, such as hives, difficulty breathing, or swelling.,Follow up with your doctor for repeat procedures as needed.
Apply a thin layer to the affected area once daily, usually for 2 to 4 weeks.,Wash hands before and after application unless treating the hands.,Do not cover the treated area with bandages or wraps unless directed.,Avoid contact with eyes, nose, mouth, or broken skin. If contact occurs, rinse with water.,Notify your doctor if condition worsens, does not improve within 4 weeks, or if severe irritation or allergic reaction develops.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHAMOLIN vs AKRINOL, answered by our medical review team.
ETHAMOLIN is a Sclerosing Agent that works by Ethamolin (ethanolamine oleate) is a sclerosing agent that causes irritation of the vascular endothelium, leading to thrombosis, inflammation, and fibrosis of the vein wall, resulting in obliteration of varicose veins or esophageal varices.. AKRINOL is a Topical Retinoid that works by Not available; likely a combination product with antihistaminic and sympathomimetic actions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHAMOLIN and AKRINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHAMOLIN is: 5% solution intravenously, 0.1-0.3 m L per injection site, maximum 5 m L per site, repeated at 5-7 day intervals if needed.. The standard adult dose of AKRINOL is: Adults: 100 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHAMOLIN and AKRINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHAMOLIN is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk: Ethamolin (ethanolamine oleate) is contraindicated in pregnant women due to known teratogenicity in animal studies and . AKRINOL is classified as Category C. FDA Pregnancy Category D. First trimester: risk of CNS defects and spontaneous abortion. Second/third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.